LS Instruments secures investment to boost growth in the pharmaceutical sector

Founded in 2010 as a public limited company, LS Instruments AG (LSI), a spin-off of the University of Fribourg, is a technology leader in the field of optical characterization of nanoparticles. The patented technology, which was developed in close cooperation with Innosuisse (formerly CTI) and the University of Fribourg, is used in basic research as well as in product development and quality control in various industries. From its location in Fribourg, the LSI team with 10 employees serves an international clientele in over 34 countries worldwide. The core of the business is the sale of instruments such as the NanoLab for particle sizing or the Rheolab providing access to the sample's viscoelastic properties.

Increasing investments in the pharmaceutical industry, increasing regulatory requirements for medical products, and the recent successful launch of vaccines based on mRNA technology related to COVID-19 have led to a global increase in demand for high-precision nanoparticle analytical solutions.

In collaboration with existing customers and Solvias, a leading international analytical service provider (CRO) in the pharmaceutical sector, LSI has achieved outstanding results in vaccine, cell and gene therapy research.

Attracting private investors

Thanks to its technological edge, its successfully applied analytical solutions worldwide and a customer demand pick-up, LSI was able to successfully complete an oversubscribed capital increase in December 2021. The financial resources, which come exclusively from a group of private investors, will be used primarily for product development and international expansion. In this context, several new jobs will be created at the Fribourg site. The size of the capital increase has been agreed with the investors not to be disclosed.

(Press release / SK)